Bristol-Myers Squibb (BMY)
61.68
+2.85 (4.84%)
Upcoming Events
Latest Headlines
RBC Capital on Bristol-Myers Squibb Co. (BMY): 'Strong Execution Expected But May be Overshadowed by Key Binary Catalyst'
October 19, 2026 9:28 AM - StreetInsider
Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
October 19, 2026 6:59 AM - BizWire
Bristol-Myers Squibb Co. (BMY) PT Lowered to $60 at HSBC
October 19, 2026 1:32 AM - StreetInsider
Bernstein SocGen on Bristol-Myers Squibb Co. (BMY): 'Stock remains constrained by questions & remaining catalyst pathway'
October 13, 2026 8:59 AM - StreetInsider
Bristol-Myers Squibb Co. (BMY) PT Lowered to $60 at Wells Fargo
October 13, 2026 5:55 AM - StreetInsider
Bristol Myers Squibb stock surges on dual phase 3 clinical trial successes
October 12, 2026 7:27 AM - StreetInsider
Bristol Myers Squibb's RYZ101 meets primary endpoint in phase 3 GEP-NET trial
October 12, 2026 6:55 AM - StreetInsider
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
October 12, 2026 6:55 AM - BizWire
Bristol Myers Squibb lung fibrosis drug meets Phase 3 trial goal
October 12, 2026 6:50 AM - StreetInsider
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
October 12, 2026 6:50 AM - BizWire
Bristol-Myers Squibb Co. (BMY) PT Lowered to $53 at Cantor Fitzgerald on Anticipated Milvexian Pressure
October 8, 2026 7:12 AM - StreetInsider
BMS drug Zenbexus cuts myeloma progression risk by 51% in trial
October 8, 2026 6:59 AM - StreetInsider
Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refr
October 8, 2026 6:59 AM - BizWire
Bristol-Myers Squibb Co. (BMY) PT Raised to $41 at Morgan Stanley
October 7, 2026 7:58 AM - StreetInsider
Form 4 BRISTOL MYERS SQUIBB CO For: Oct 02 Filed by: Gallman Cari
October 5, 2026 4:19 PM - SEC Filing
Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt
October 5, 2026 9:30 AM - StreetInsider
Leerink Downgrades Bristol-Myers Squibb Co. (BMY) to Market Perform
October 5, 2026 7:59 AM - StreetInsider
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
October 5, 2026 7:29 AM - StreetInsider
Form 4 BRISTOL MYERS SQUIBB CO For: Sep 30 Filed by: YALE PHYLLIS R
October 2, 2026 4:27 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Sep 30 Filed by: Samuels Theodore R. II
October 2, 2026 4:26 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Sep 30 Filed by: Rice Derica W
October 2, 2026 4:25 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Sep 30 Filed by: McMullen Michael R.
October 2, 2026 4:23 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Sep 30 Filed by: Arduini Peter J
October 2, 2026 4:22 PM - SEC Filing
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
October 1, 2026 6:59 AM - BizWire
FDA approves Bristol Myers Squibb's Camzyos for pediatric oHCM
September 30, 2026 5:32 PM - StreetInsider
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Ad
September 30, 2026 5:32 PM - BizWire
Wells Fargo Sees Liver Safety Risk In Bristol Admilparant Trial - Bloomberg
September 29, 2026 4:45 PM - StreetInsider
Bristol-Myers Squibb (BMY) Quickly Falls 2.5%
September 29, 2026 3:52 PM - StreetInsider
BMS Zenbexus doubles response rates in myeloma trial
September 25, 2026 10:00 AM - StreetInsider
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
September 25, 2026 10:00 AM - BizWire
Goldman Sachs on Bristol-Myers Squibb Co. (BMY): 'Complicated Setup for Upcoming Admilparant Phase 3 IPF Readout'
September 23, 2026 6:54 AM - StreetInsider
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
September 18, 2026 6:59 AM - BizWire
Faeth Therapeutics adds cancer biologist Karen Vousden to its board
September 17, 2026 4:00 PM - StreetInsider
BMS Sotyktu shows sustained efficacy in psoriatic arthritis at two years
September 17, 2026 6:59 AM - StreetInsider
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
September 17, 2026 6:59 AM - BizWire
Buy the pullback in this large pharma stock: UBS
September 17, 2026 6:00 AM - StreetInsider
Bristol-Myers Squibb (BMY) Declares $0.63 Quarterly Dividend; 4% Yield
September 16, 2026 6:59 AM - StreetInsider
Bristol Myers Squibb Announces Dividend
September 16, 2026 6:59 AM - BizWire
Bristol-Myers Squibb Co. (BMY) PT Raised to $82 at Piper Sandler
September 16, 2026 6:49 AM - StreetInsider
Form 4 BRISTOL MYERS SQUIBB CO For: Sep 09 Filed by: Massacesi Cristian
September 10, 2026 4:37 PM - SEC Filing
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
September 10, 2026 8:30 AM - StreetInsider
Bristol-Myers Squibb Co. (BMY) PT Raised to $65 at HSBC
September 10, 2026 3:28 AM - StreetInsider
Form 144 BRISTOL MYERS SQUIBB CO Filed by: Massacesi Cristian
September 9, 2026 10:28 AM - SEC Filing
BMS myeloma CAR T therapy meets primary endpoint in phase 2 trial
September 8, 2026 6:59 AM - StreetInsider
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ..
September 8, 2026 6:59 AM - BizWire
Form 4 BRISTOL MYERS SQUIBB CO For: Sep 01 Filed by: Short Bartie Wendy
September 3, 2026 4:12 PM - SEC Filing
BMS presents five-year Camzyos data for heart condition at ESC
August 31, 2026 6:05 AM - StreetInsider
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European
August 29, 2026 11:00 AM - BizWire
Form 4 BRISTOL MYERS SQUIBB CO For: Aug 25 Filed by: Holzer Phil M
August 26, 2026 4:18 PM - SEC Filing
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026 9:20 AM - StreetInsider
Form 144 BRISTOL MYERS SQUIBB CO Filed by: Holzer Phil M
August 25, 2026 11:04 AM - SEC Filing
UBS Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
August 20, 2026 10:02 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
August 17, 2026 6:56 AM - StreetInsider
FDA grants accelerated approval to Bristol Myers Squibb's Zenbexus
August 13, 2026 5:12 PM - StreetInsider
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multip
August 13, 2026 5:12 PM - BizWire
Cytokinetics sues Bristol-Myers Squibb over aficamten patent dispute
August 13, 2026 9:26 AM - StreetInsider
Atrium Therapeutics receives $15M milestone from Bristol Myers Squibb
August 13, 2026 8:01 AM - StreetInsider
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
August 13, 2026 8:00 AM - PR NewsWire
Bristol Myers Squibb plans $2.3B manufacturing campus in Houston
August 10, 2026 9:02 AM - StreetInsider
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
August 10, 2026 9:01 AM - BizWire
Morgan Stanley tracks US drug market prescriptions for week ending July 31
August 7, 2026 12:04 PM - StreetInsider
Form SCHEDULE 13G BRISTOL MYERS SQUIBB CO Filed by: STATE STREET CORP
August 7, 2026 8:56 AM - SEC Filing
AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
August 5, 2026 8:31 AM - StreetInsider
Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
August 5, 2026 8:14 AM - StreetInsider
'No Discussions' Over Astrazeneca-Bristol Myers Deal, Senior Source Says - Reuters
August 5, 2026 8:07 AM - StreetInsider
Argus Upgrades Bristol-Myers Squibb Co. (BMY) to Buy
August 5, 2026 7:55 AM - StreetInsider
Form 4 BRISTOL MYERS SQUIBB CO For: Aug 01 Filed by: Massacesi Cristian
August 4, 2026 4:11 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Aug 01 Filed by: Gallman Cari
August 4, 2026 4:08 PM - SEC Filing
RBC Capital on Bristol-Myers Squibb's (BMY) AZN Deal Feedback
August 4, 2026 8:48 AM - StreetInsider
Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?
August 3, 2026 11:24 AM - StreetInsider
AstraZeneca reviews potential Bristol Myers deal, Barclays comments
August 3, 2026 8:17 AM - StreetInsider
Bristol-Myers Squibb (BMY) call put ratio 1 call to 1.5 puts into share price up before the bell
August 3, 2026 5:51 AM - StreetInsider
Stocks expected to have increasing option volume: BMY AZN MRK GILD MRNA PFE AMGN PLTR MAR AMD CAT MRK MCD REPL
August 3, 2026 5:44 AM - StreetInsider
U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
August 1, 2026 10:00 AM - StreetInsider
Bristol-Myers Squibb Co. (BMY) PT Raised to $55 at Cantor Fitzgerald
July 31, 2026 10:22 AM - StreetInsider
Bristol-Myers Squibb Co. (BMY) PT Raised to $73 at JPMorgan
July 31, 2026 8:56 AM - StreetInsider
Bristol-Myers Squibb Co. (BMY) PT Raised to $65 at Wells Fargo
July 31, 2026 8:35 AM - StreetInsider
Bristol-Myers Squibb Co. (BMY) PT Raised to $64 at RBC Capital
July 31, 2026 8:14 AM - StreetInsider
Bristol-Myers Squibb Co. (BMY) PT Raised to $70 at Truist Securities
July 31, 2026 7:09 AM - StreetInsider
Bristol-Myers Squibb Co. (BMY) PT Raised to $75 at Guggenheim
July 31, 2026 6:59 AM - StreetInsider
Form 10-Q BRISTOL MYERS SQUIBB CO For: Jun 30
July 30, 2026 11:11 AM - SEC Filing
Bristol-Myers Squibb raises annual outlook as Q2 tops estimates; shares up
July 30, 2026 7:25 AM - StreetInsider
Form 8-K BRISTOL MYERS SQUIBB CO For: Jul 30
July 30, 2026 7:06 AM - SEC Filing
Bristol-Myers Squibb (BMY) Tops Q2 EPS by 43c, Beats on Revenue; Offers FY26 Guidance
July 30, 2026 7:00 AM - StreetInsider
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026
July 30, 2026 6:59 AM - BizWire
Bristol-Myers Squibb (BMY) call put ratio 1 call to 1 put into quarter results
July 29, 2026 11:31 AM - StreetInsider
Raymond James on Bristol-Myers Squibb Co. (BMY): 'we do not view the ZEPHYR data as signaling a risk to Cobenfy across indications'
July 27, 2026 2:29 PM - StreetInsider
BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
July 27, 2026 8:23 AM - StreetInsider
Full Article List
